Yüklüyor......

A new class of bronchodilator improves lung function in COPD: a trial with GSK961081

GSK961081 is a bifunctional molecule demonstrating both muscarinic antagonist and β-agonist activities. This was a 4-week, multicentre, randomised, double-blind, double-dummy, placebo and salmeterol controlled parallel group study. Doses ranging across three twice-daily doses and three once-daily do...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Wielders, Pascal L.M.L., Ludwig-Sengpiel, Andrea, Locantore, Nicholas, Baggen, Suus, Chan, Robert, Riley, John H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: European Respiratory Society 2013
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3787816/
https://ncbi.nlm.nih.gov/pubmed/23429913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/09031936.00165712
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!